CapsoVision Inc (NASDAQ:CV) Misses Q3 2025 Earnings and Revenue Estimates

Financial Performance Overview

CAPSOVISION INC (NASDAQ:CV) reported its third-quarter 2025 financial results, revealing a performance that fell short of analyst expectations on key profitability and revenue metrics. The medical technology company posted a Non-GAAP earnings per share (EPS) of -$0.17, which was notably wider than the estimated loss of -$0.1288. This represents an earnings miss of approximately 32%.

On the revenue front, the company reported sales of $3.54 million for the quarter, which did not meet the analyst consensus estimate of $3.79 million. The company's performance against key estimates is summarized below:

• Reported Non-GAAP EPS: -$0.17
• Estimated Non-GAAP EPS: -$0.1288
• Reported Revenue: $3.54 million
• Estimated Revenue: $3.79 million

Market Reaction and Price Action

The market's immediate reaction to the earnings release appears to be neutral in after-hours trading, with no significant price movement indicated. However, looking at the broader performance windows provides a more complete picture of the stock's recent trajectory. The share price has demonstrated substantial strength in the lead-up to the earnings announcement, with significant gains over the past several weeks. This suggests that investor sentiment had been building positively ahead of the report, potentially on optimism for a stronger beat.

Press Release Summary

The company's press release, dated November 13, 2025, served as the official announcement of its Q3 2025 financial results. As a commercial-stage company, the focus remains on the development and commercialization of its advanced imaging and AI-enabled capsule endoscopy solutions, including its flagship CapsoCam Plus product and the CapsoCloud software platform. The release formally communicated the financial figures to the market but, based on the provided context, did not include a specific financial outlook for the upcoming quarters. The absence of forward guidance in this report is a neutral factor and does not inherently explain the market's reaction.

Looking Ahead: Analyst Estimates for Future Periods

With the Q3 results now public, investor attention will shift to the company's ability to meet future targets. Current analyst estimates provide a benchmark for expectations in the coming periods. For the crucial fourth quarter of 2025, analysts are projecting a continued loss per share and a sequential increase in revenue.

• Q4 2025 EPS Estimate: -$0.12875
• Q4 2025 Sales Estimate: $4.59 million

For the full 2025 fiscal year, the Street is anticipating:

• Full-Year 2025 EPS Estimate: -$0.8343
• Full-Year 2025 Sales Estimate: $14.59 million

Achieving or exceeding these estimates, particularly a path toward narrowing losses, will be critical for sustaining investor confidence following the Q3 miss.

For a detailed breakdown of historical earnings, future estimates, and analyst revisions, you can review the data here: CapsoVision Earnings & Estimates.

Disclaimer: This article is for informational purposes only and is not intended as investment advice. All investment and financial decisions involve risk, including the loss of principal, and readers should conduct their own research and consult with a qualified financial advisor before making any decisions.